Related Experiment Video

Updated: Apr 17, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.5K

BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance

Yun Dai1, Steven Grant

  • 1a Division of Hematology/Oncology; Department of Medicine ; Virginia Commonwealth University and the Massey Cancer Center ; Richmond , VA USA.

Autophagy
|February 22, 2015
PubMed

Insights

Anticancer treatments can trigger autophagy, a cell survival process that may lead to drug resistance. This study explores how BH3-only proteins influence this process, offering new insights into overcoming treatment resistance.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cellular Biology

Background:

  • Anticancer agents often induce autophagy, a cytoprotective mechanism.
  • Autophagy can counteract apoptosis, contributing to acquired drug resistance.
  • The BCL2 family regulates both apoptosis and autophagy, but BH3-only proteins' role in autophagy is unclear.

Purpose of the Study:

  • To investigate the role of pro-apoptotic BH3-only proteins in regulating autophagy.
  • To explore the mechanisms by which BH3-only proteins affect autophagy in the context of acquired drug resistance.

Main Methods:

  • Utilizing molecular biology techniques to study BCL2 family protein interactions.
  • Analyzing the impact of BH3-only proteins on autophagy induction and suppression.
  • Investigating drug-resistant cancer models.

Main Results:

  • BH3-only proteins play a critical role in modulating autophagy.
  • Understanding these interactions may reveal new therapeutic strategies.
  • Specific BH3-only proteins were identified as key regulators of autophagy in drug-resistant cells.

Conclusions:

  • Pro-apoptotic BH3-only proteins are significant regulators of autophagy.
  • Targeting BH3-only proteins could be a strategy to overcome drug resistance.
  • Further research into BCL2 family protein networks is warranted for novel cancer therapies.
Keywords:
BCL2L11/Bimacquired drug-resistanceautophagymultiple myelomatargeted therapy

More Related Videos

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.6K
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

3.3K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
5.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K